期刊文献+

Mechanism of Arsenic Trioxide Inhibiting Angiogenesis in Multiple Myeloma 被引量:1

Mechanism of Arsenic Trioxide Inhibiting Angiogenesis in Multiple Myeloma
下载PDF
导出
摘要 In order to explore the molecular mechanism of arsenic trioxide treating multiple myeloma (MM) via inhibition of angiogenesis, the expression of brain derived neurotrophic factor (BDNF) and its specific receptor TrkB in human MM cell line KM3 and endothelial cell line ECV304 was detected by Western blotting. The angiogenic activity was evaluated by wound migration assay and tubule formation assay in vitro. The results showed that BDNF was detected in the MM cells and TrkB in the endothelial cells. Furthermore, 100 ng/mL BDNF could significantly induced endothelial cell tubule formation and wound migration. As2O3 depressed the expression of BDNF and TrkB in the dose- and time-dependent manner. As2O3 inhibited BDNF-induced wound migration and capillary tube formation. It was concluded that BDNF is a novel angiogenic protein as well as VEGF and has a relation with the pathogenesis of MM. As2O3 interrupts a paracrine loop between MM cells and endothelial cells by down-regulating the TrkB expression in endothelial cells and inhibiting BDNF production in MM cells, finally resulting in inhibition of MM angiogenesis. This is probably one part of the mechanisms of the As2O3 treating MM via the inhibition of angiogenesis. In order to explore the molecular mechanism of arsenic trioxide treating multiple myeloma (MM) via inhibition of angiogenesis, the expression of brain derived neurotrophic factor (BDNF) and its specific receptor TrkB in human MM cell line KM3 and endothelial cell line ECV304 was detected by Western blotting. The angiogenic activity was evaluated by wound migration assay and tubule formation assay in vitro. The results showed that BDNF was detected in the MM cells and TrkB in the endothelial cells. Furthermore, 100 ng/mL BDNF could significantly induced endothelial cell tubule formation and wound migration. As2O3 depressed the expression of BDNF and TrkB in the dose- and time-dependent manner. As2O3 inhibited BDNF-induced wound migration and capillary tube formation. It was concluded that BDNF is a novel angiogenic protein as well as VEGF and has a relation with the pathogenesis of MM. As2O3 interrupts a paracrine loop between MM cells and endothelial cells by down-regulating the TrkB expression in endothelial cells and inhibiting BDNF production in MM cells, finally resulting in inhibition of MM angiogenesis. This is probably one part of the mechanisms of the As2O3 treating MM via the inhibition of angiogenesis.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2006年第1期43-46,共4页 华中科技大学学报(医学英德文版)
基金 ThisprojectwassupportedbyagrantfromtheNaturalSciecesFoundationofHubei,China(No.2003ABB017).
关键词 arsenic trioxide brain derived neurotrophic factor multiple myeloma ANGIOGENESIS arsenic trioxide brain derived neurotrophic factor multiple myeloma angiogenesis
  • 相关文献

参考文献10

  • 1McCafferty-Grad J,Bahlis NJ,Krett Net al.Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells[].Molecular Cancer Therapeutics.2003
  • 2Roboz G J,Dias S,Lam Get al.Arsenic trioxide in-duces dose-and ti me-dependent apoptosis of endotheli-umand may exert an antileukemic effect via inhibition of angiogenesis[].Blood.2000
  • 3Soignet S L,Maslak P,Wang Z Get al.Complete re-mission after treat ment of acute promyelocytic leukemia with arsenic trioxide[].The New England Journal of Medicine.1998
  • 4Bahlis NJ,Jordan-Mc Murry I,Grad J Met al.PhaseⅠresults froma PhaseⅠ/Ⅱstudy of arsenic trioxide(As2O3)and ascorbic acid(AA)in relapsed and che-morefractory multiple myeloma[].Blood.2001
  • 5Miller W H,Schipper H M.Mechanisms of action of arsenic trioxide1[].Cancer Research.2002
  • 6Yahata Y,Shirakata Y,Tokumaru Set al.Nuclear translocation of phosphorylated STAT3Is essential for vascular endothelial growth factor-induced human der-mal microvascular endothelial cell migration and tube formation[].Journal of Biological Chemistry.2003
  • 7Hussein M A,Mason J,Ravandi Fet al.A PhaseⅡclinical study of arsenic trioxide(ATO)in patients(Pts)with relapsed or refractory multiple myeloma(MM):a preli minary report[].Blood.2001
  • 8Hussein M A.Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma[].The Oncologist.2002
  • 9Sharma G D,He J C,Bazan H.p38and ERK1/2co-ordinate cellular migration and proliferationin epithelial wound healing:evidence of cross-talk activation be-tween MAP kinase cascades[].Journal of Biological Chemistry.2003
  • 10Harousseau J L,Shaughnessy J,Richardson P.Multi-ple myeloma[].Hematology.2004

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部